<DOC>
	<DOCNO>NCT01056679</DOCNO>
	<brief_summary>The purpose study determine within scope trial maximum tolerate dose ( MTD ) lenalidomide combination AVD .</brief_summary>
	<brief_title>Adriamycin , Vinblastine , DTIC Revlimid Elderly Hodgkin Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Hodgkin Lymphoma , intermediate advance stage Age &gt; 60 &lt; 75 year ECOG 2 good No major organ dysfunction Ability take aspirin LMW Heparin HL composite lymphoma Prior use lenalidomide Prior use chemo radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>